Clinical Trial

Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL

Study acronym: ZOOM
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated May 22, 2025 (before its estimated December 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is a multi-center, prospective cohort study. The main purpose of study is to evaluate the efficacy and safety of Orelabrutinib combined with Zuberitamab in the initial treatment of MZL Main efficacy indicators Complete response rate (CR) at the end of combination therapy.
Trial Details
NCT Number NCT06985472
Lead Sponsor Li Zhiming
Conditions Initial MZL, Untreated MZL, BTKi, CD20
Enrollment 33 participants
Start Date 2024-11-13
Primary Completion 2025-12-01 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-05-22